<unk>  is the clinical syndrome that results from excessive secretion of growth hormone (GH). Its annual incidence is six to eight per million people. The mean age at diagnosis is 40 to 45 years. The most common cause of<unk>  is a somatotroph (GH-secreting) adenoma of the anterior pituitary. Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated. There is no life-threatening cause of<unk> . However, if left untreated, 30% of patients with<unk>  may progress to develop cardiovascular manifestations, pulmonary dysfunction, and cerebral complications. These comorbidities will increase the mortality rate. IGF-1 should be measured in patients without the typical manifestations of<unk> , but who have several of these associated conditions: sleep apnea syndrome, type 2 diabetes mellitus, debilitating arthritis, carpal tunnel syndrome, hyperhidrosis, and hypertension. Katznelson et al. recommends Transsphenoidal surgery as the primary therapy in most patients. Endocrine society clinical practice guideline on<unk>  also recommends Radiation therapy in the setting of residual tumor mass following surgery, and if medical treatment is unavailable, unsuccessful, or not tolerated.
Acromegaly
Thyromegaly
Hyperaldosteronism
Pheochromocytoma
Hypoaldosteronism
Hyerthyroidism
Insulinoma
Thyroid adenoma